Syngene International Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/w5c14b3cbvj1912p64uonwno.pdf

Key Takeaways


Revenue Performance & the Biotech Slowdown

Hunt: "Long term sector fundamentals remain strong and we expect continued growth but at a lower level in the second half of the year, this short-term slowing in the US biotech segment is reflected in our latest outlook."

Margin Structure & Cost Dynamics


Capacity Expansion & Strategic Build-Out

Hunt: "I am pleased to report a strong set of results for the second quarter and first half of the financial year, particularly in our Development and Manufacturing Services."

Investment Posture & H2 Priorities

Biswas: "During the second half of the year, we will continue to invest in new science, technology and digitization, as well as building capacity to support future growth, while balancing discretionary expenditure in order to maintain margins."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthMid-teens constant-currency growth (revised down from high-teens)FY24 full year
Investment spendContinue investing in science, technology, digitization and capacityH2 FY24
Margin managementBalance discretionary expenditure to maintain margins while investingH2 FY24
Stelis acquisitionComplete acquisition of multi-modal facility (Unit 3) from Stelis BiopharmaIn progress, no date given

Key Metrics

MetricQ2 FY24
Revenue from operations₹910 crores, up 18.5% YoY, ~15% at constant currency
Reported revenue₹932 crores, up 19% YoY
EBITDA from operations₹254 crores, up 17.4% YoY
EBITDA from operations margin27.9%, down 27 bps YoY
Reported EBITDA₹276 crores, up 19% YoY
Reported EBITDA margin29.6%, flat YoY
EBIT from operations₹149.4 crores, up 18.4% YoY
EBIT from operations margin16.4%, down 1 bps YoY
PAT before exceptional items₹122 crores, up 20% YoY
PAT margin (before exceptional items)13.1%, up 7 bps YoY
PAT after exceptional items₹117 crores, up 14% YoY
Exceptional item (net of tax)₹5.3 crores, transaction costs for Stelis Biopharma facility acquisition
Revenue growth guidance (constant currency)Mid-teens for FY24, revised from high teens
Cash and cash equivalents₹168.3 crores as of 30 Sep 2023
Total borrowings₹519.9 crores as of 30 Sep 2023